Alkeon Capital Management
ANRO icon

Alkeon Capital Management’s Alto Neuroscience ANRO Stock Holding History

Alkeon Capital Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.69M Sell
102,101
-125,000
-55% -$2.89M ﹤0.01% 104
2026
Q1 		$5.11M Sell
227,101
-250,000
-52% -$4.63M 0.01% 99
2025
Q4 		$8.49M Hold
477,101
– – 0.01% 110
2025
Q3 		$1.92M Hold
477,101
– – ﹤0.01% 106
2025
Q2 		$1.05M Hold
477,101
– – ﹤0.01% 103
2025
Q1 		$1.03M Hold
477,101
– – ﹤0.01% 105
2024
Q4 		$2.02M Sell
477,101
-457,803
-49% -$2.86M ﹤0.01% 93
2024
Q3 		$10.7M Hold
934,904
– – 0.02% 88
2024
Q2 		$9.99M Buy
+934,904
New +$12.2M 0.02% 96

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Alkeon Capital Management's ANRO Position: Q2 2026 in Review

Alkeon Capital Management reduced its Alto Neuroscience (ANRO) stake by 55% in Q2 2026, selling an estimated $2.89M and leaving 102,101 shares worth $2.69M. The position accounts for ﹤0.01% of the portfolio, ranked #104.

Alkeon Capital Management first reported a position in ANRO in Q2 2024 and has held it in 9 quarters since. The position peaked at $10.7M in Q3 2024. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Alkeon Capital Management held 102,101 shares of Alto Neuroscience worth $2.69M as of Q2 2026.
  • Alkeon Capital Management sold 125,000 Alto Neuroscience shares in Q2 2026, an estimated $2.89M.
  • Alto Neuroscience made up ﹤0.01% of Alkeon Capital Management's portfolio in Q2 2026, its #104 holding.
  • Alkeon Capital Management first reported a position in Alto Neuroscience in Q2 2024 and has held it in 9 quarters since.
  • Alkeon Capital Management's Alto Neuroscience position peaked at $10.7M in Q3 2024.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Alkeon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.